


HeartLung Technologies Secures CMS Reimbursement for AutoChamber™ with New HCPCS Code

HeartLung proudly announces that CMS has approved a new HCPCS code for AutoChamber™ AI reporting cardiac chambers volume and left ventricular mass in CT scans

HOUSTON, TX, UNITED STATES, April 2, 2025 /EINPresswire.com/ -- [HeartLung Technologies](https://www.heartlungtechnologies.com) is pleased to announce that the Centers for Medicare & Medicaid Services (CMS) has assigned a new Healthcare Common Procedure Coding System ([HCPCS](https://www.cms.gov/medicare/coverage/policies/2020s/g0183))

[reimbursement code G0183](https://www.cms.gov/medicare/coverage/policies/2020s/g0183) that allows for reimbursement of HeartLung's [AutoChamber™](https://www.heartlungtechnologies.com) AI for reporting cardiac chambers volume and left ventricular mass in existing CT scans. This new code, which went into effect on April 1, 2025, offers a reimbursement rate of \$88.05 per each AutoChamber™ AI report.



The image shows a bifold brochure for AutoChamber. The left side is titled "Before AutoChamber" and "After AutoChamber", comparing traditional CT scan results with AI-enhanced results. The right side is titled "Introducing AutoChamber" and includes a "What Are The Main Benefits of AutoChamber" section with bullet points on value generation, integration, and turnaround time. It also features two case examples and a section on "People that could have been saved by AutoChamber".

AutoChamber Bifold 2025 - Front

“

This is an incredible achievement for HeartLung Technologies. It not only validates AutoChamber's FDA Breakthrough designation but also ensures patients can benefit from our lifesaving AI solutions.”

Dr. Morteza Naghavi, MD

"This is an incredible achievement for HeartLung Technologies," said Dr. Morteza Naghavi, CEO of HeartLung Technologies. "The CMS reimbursement not only validates the clinical value of AutoChamber's FDA Breakthrough designation but also ensures that more patients can benefit from our lifesaving AI solutions."

AutoChamber™ is designed to work with both non-contrast and contrast-enhanced chest CT scans, delivering precise measurements of cardiac volume, cardiac chamber volumes, and left ventricular wall mass. This AI-driven tool identifies cardiomegaly and enlargement of specific cardiac

chambers, such as the left atrium (LA) and left ventricle (LV), which are frequently overlooked in

standard scans. By detecting these conditions early, AutoChamber™ AI aids in preventing life-threatening diseases like stroke, heart failure, and atrial fibrillation. The new HCPCS code facilitates reimbursement for this innovative technology, broadening its availability to patients across the United States.

The inclusion of the new HCPCS code in the April 2025 Hospital Outpatient Prospective Payment System (OPPS) update highlights CMS's dedication to fostering medical innovation. HeartLung Technologies continues to lead the way in developing AI-driven healthcare solutions that transform patient care and support healthcare providers.

This represents a major milestone in HeartLung's journey to advancing preventive medicine, saving lives and cutting costs with AI. Our healthcare system needs many more initiatives like this for early detection and prevention of fatal diseases vs. treating late-stage diseases which consume most of our healthcare budget.

About HeartLung Technologies:

HeartLung Technologies aims to help people live long by eliminating preventable deaths caused by heart attacks, lung cancer, osteoporosis, chronic pulmonary obstructive disease (COPD), fatty liver disease, and other deadly medical conditions. HeartLung's team of industry-leading physicians and engineers are dedicated to increasing people's life-span and health-span by starting with taking out America's most deadly killers: heart disease and lung cancer. HeartLung is innovating for the millions of Americans and many more worldwide who can benefit from early detection of preventable fatal diseases. HeartLung.AI is a portfolio company of American Heart Technologies (AHT) founded by Dr. Morteza Naghavi, a leader in preventive cardiology and health-tech, former faculty of Texas Heart Institute and University of Texas in 2007. AHT was established as a vehicle for commercialization of innovative healthcare solutions, three of which received FDA approval and were commercialized under portfolio companies Endothelix Inc., and CardioNexus Corp, and HeartLung Corp.

SAMPLE REPORT

Your Cardiac Chambers Volumetry Report

Patient Name: Name, None
ID: None
Date of Exam: 07/30/2023
Date of Birth: 02/02/1990
Gender: Male

AutoChamber™
Powered by HeartLung Technologies
[To learn more visit www.heartlung.ai](http://www.heartlung.ai)

Adjustable for Males Adjusted by Body Surface Area (BSA)

Chamber	Volume (cc)	Percentile
LA (Left Atrium)	76.5	38.4 82th
LV (Left Ventricle)	158.1	78.3 95th
RA (Right Atrium)	119.7	62.1 95th
RV (Right Ventricle)	143.6	97.2 91th
LWV (Left Ventricular Wall)	143.6	73.8 90th

Cardiothoracic Ratio: 0.44
* Adjusted by body surface area (BSA)

Percentile (side view)

Percentile (front view)

Percentile (cross-sectional view)

Percentile (cross-sectional view)

Reference Database
The above percentiles are calculated based on your gender and body surface area (BSA) using reference data from 10331 people who participated in the Multi-Ethnic Study of Atherosclerosis (MESA), sponsored by the National Institutes of Health. Using AutoChamber™ measurements and their clinical evaluation, healthcare providers can investigate asymptomatic patients who are unaware of their risk of heart failure, atrial fibrillation, stroke and other life-threatening conditions associated with enlarged heart, enlarged cardiac chambers, and left ventricular hypertrophy that may warrant additional risk assessment or follow-up. The actual level of risk must be evaluated based on your care provider's comprehensive assessment. Colors and cut-offs are based on institutional settings and are not an indication for treatment. This report serves as an AI-enabled quantitative imaging tool to a qualified care provider to make the diagnosis based on comprehensive evaluation.

Physician's Recommendation
Based on the results, one or more of your cardiac measurements are elevated because they exceed the 75th percentile. We strongly recommend that you consult with your care provider for necessary follow-up and evaluation.

Detect Hidden Heart Disease

Catch What A Calcium Score Can't

This graph shows a significant percentage of people who are classified as low risk based on coronary artery calcium (CAC) scores of zero or below 100 have an enlarged left atrium (LA) that puts them at a high risk of atrial fibrillation (AF) and stroke.

Similar results were found for enlarged left ventricle (LV) putting patients at high risk of heart failure (HF).

References:
* Hagan AD, Reeves AP, Weiss CT, Jiang CL, Liu J, et al. Enlarged Left Atrium, Left Ventricular Hypertrophy, and Coronary Calcium in the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Cardiol*. 2018;121:1024-1030.
 * Hagan AD, Reeves AP, Weiss CT, Jiang CL, Liu J, et al. Enlarged Left Atrium, Left Ventricular Hypertrophy, and Coronary Calcium in the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Cardiol*. 2018;121:1024-1030.

Simple & Easy Workflow Integration

How It Works
AutoChamber™ for Diagnostic Imaging Centers

HeartLung Technologies Co. is the first FDA-approved AI with "FDA-cleared" designation for opportunistic screening and detection of hidden heart disease in CT scans.

AutoChamber Bifold 2025 - Back

HeartLung Technologies is committed to revolutionizing preventive healthcare through innovative AI solutions. For more information about AutoChamber™ and its advantages, please visit www.heartlung.ai. and www.americanhearttechnologies.com.

Marlon Montes
HeartLung Technologies
+1 310-510-6004
contact@heartlung.ai

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/799556575>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.